Clinical trials
Terminated Muscular Dystrophy, Duchenne trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 8 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 53 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| BioMarin Pharmaceutical | 6 |
| Pfizer | 6 |
| Sarepta Therapeutics, Inc. | 6 |
| PTC Therapeutics | 5 |
| Kyntra Bio | 3 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| Processa Pharmaceuticals | 2 |
| Santhera Pharmaceuticals | 2 |
| Akashi Therapeutics | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Dystrophy, Duchenne | 53 |
| Muscular Dystrophies | 13 |
| Neuromuscular Diseases | 5 |
| Muscular Diseases | 4 |
| Genetic Diseases, Inborn | 3 |
| Musculoskeletal Diseases | 3 |
| Amyotrophic Lateral Sclerosis | 2 |
| Genetic Diseases, X-Linked | 2 |
| Muscular Disorders, Atrophic | 2 |
| Nervous System Diseases | 2 |
Trials
Showing 51 to 53 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.